Drug Non-Adherence Costs Manufacturers Billions Of Dollars In Revenues – Study
This article was originally published in The Pink Sheet Daily
Capgemini’s calculations of potential pharmaceutical revenues if patients were fully compliant with their drug therapy regimens suggest revenues in the U.S. would be nearly 60% higher. But even small changes have sizeable revenue impact.
You may also be interested in...
Pharmaceutical companies are spending more to help patients adhere to their therapeutic regimens – an almost universally recognized way to improve health outcomes and pharma’s bottom line. But an unclear legal and regulatory climate and poor understanding of the adherence problems it is trying to solve means industry isn’t trumpeting what could be one of its best health care value arguments.
Medication Adherence Budgets Rising At Pharma Firms, Report Says, But Impact Still Hard To Calculate
Pharmaceutical companies are investing more money into medication adherence programs, but measuring the success of these programs remains a challenge. Consultants are recommending building adherence plans into the development of a drug, with an emphasis on understanding patients’ approaches to compliance.
A study conducted for the National Community Pharmacists Association assigns chronic medication users report card grades based on rates of different non-adherent behaviors and describes the most common reasons along with some possible remedies.